As an esteemed Professor of Oncology at the Roswell Park Cancer Institute and a member of the Department of Cell Stress Biology, Mikhail Blagosklonny engages in groundbreaking research in targeted cancer therapies and anti-aging medicines.
Specifically, Blagosklonny’s research includes biogerontology and Target of Rapamycin (TOR) signaling, key components of his anticancer and anti-aging strategies.
His research focuses on the idea that while molecular damage occurs with aging, humans don’t live long enough to die from it. According to Research Gate, an advocate of the drug rapamycin, which is a rare bacterium from Eater Island, Mikhail Blagosklonny believes the drug is not only a cancer treatment; it is a potential fountain of youth that may postpone certain aging-related diseases and delay the effects of normal aging by putting cells into a stress-resistant mode.
While Mikhail Blagosklonny’s findings mirror that of other researchers, he has gone a step further, taking the drug himself to prove that there are no side effects. Since rapamycin has been available for 15 years with no serious side effects, Blagosklonny is eager to explore off-label uses that may significantly improve the lives of older individuals.
A graduate of the First Pavlov State Medical University of St. Petersburg, ç holds an M.D. in Internal Medicine and a PhD in Experimental Medicine and Cardiology. Blagosklonny’s previous positions including Associate Professor of Medicine at New York Medical College and Senior Scientist at Ordway Research Institute.
In addition to publishing more than 270 papers of his own, Blagosklonny is the editor-in-chief of three medical and scientific journal publications; Aging, Cell Cycle and Oncotarget.
Impact Journals reported that Mikhail Blagosklonny is also Associate Editor of Cancer Research, Autophagy, the International Journal of Cancer, American Journal of Pathology and PLOS ONE.